Ansam Sinjab,Guangchun Han,Warapen Treekitkarnmongkol,Kieko Hara,Patrick M. Brennan,Minghao Dang,Dapeng Hao,Ruiping Wang,Enyu Dai,Hitoshi Dejima,Jiexin Zhang,Elena Bogatenkova,Beatriz Sanchez-Espiridion,Kyle Chang,Danielle R. Little,Samer Bazzi,Linh M. Tran,Kostyantyn Krysan,Carmen Behrens,Dzifa Y. Duose,Edwin R. Parra,Maria Gabriela Raso,Luisa M. Solis,Junya Fukuoka,Jianjun Zhang,Boris Sepesi,Tina Cascone,Lauren Averett Byers,Don L. Gibbons,Jichao Chen,Seyed Javad Moghaddam,Edwin J. Ostrin,Daniel Rosen,John V. Heymach,Paul Scheet,Steven M. Dubinett,Junya Fujimoto,Ignacio I. Wistuba,Christopher S. Stevenson,Avrum Spira,Linghua Wang,Humam Kadara

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers

Supplementary Text from CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma

Supplementary Tables 1 - 3 from Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Supplementary Text from Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

Supplementary Fig S21-S24 from Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing

Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Supplementary Figures S1-S21 from Integrated Multi-Omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Methods, Figures 1-14 from A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens

Supplementary Data 1 from Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade